Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Allogene Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALLO
Nasdaq
8731
https://allogene.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Allogene Therapeutics Inc
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR Tâ„¢ Target for Small Cell Lung Cancer
- Jan 25th, 2023 1:30 pm
Allogene Therapeutics (ALLO) Soars 15.7%: Is Further Upside Left in the Stock?
- Jan 25th, 2023 7:52 am
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
- Jan 24th, 2023 1:30 pm
Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival
- Jan 20th, 2023 6:00 pm
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
- Jan 19th, 2023 2:40 pm
Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab
- Jan 18th, 2023 3:38 pm
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
- Jan 17th, 2023 9:05 pm
Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why
- Jan 16th, 2023 3:25 pm
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
- Jan 12th, 2023 2:56 pm
Amarin's (AMRN) Q4 Preliminary Revenues Top Expectations
- Jan 12th, 2023 12:14 am
Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock?
- Jan 11th, 2023 1:35 pm
Emergent (EBS) to Start Restructuring Plan, Lays Off 5% Workforce
- Jan 10th, 2023 5:06 pm
Moderna (MRNA) Reports 2023 Business View & Pipeline Updates
- Jan 10th, 2023 4:55 pm
FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA
- Jan 6th, 2023 6:50 pm
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Jan 4th, 2023 1:30 pm
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
- Jan 3rd, 2023 1:00 pm
Down -41.38% in 4 Weeks, Here's Why Allogene Therapeutics (ALLO) Looks Ripe for a Turnaround
- Dec 29th, 2022 2:35 pm
15 Most Shorted Stocks Hedge Funds Are Buying
- Dec 28th, 2022 5:32 pm
Wall Street Analysts Think Allogene Therapeutics (ALLO) Could Surge 159%: Read This Before Placing a Bet
- Dec 8th, 2022 2:55 pm
Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?
- Dec 2nd, 2022 4:31 pm
Scroll